M
Melanie A. Leiby
Researcher at Merck & Co.
Publications - 8
Citations - 7165
Melanie A. Leiby is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Medicine. The author has an hindex of 5, co-authored 6 publications receiving 5413 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
Julie R. Brahmer,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Jessica McLean,Yue Shentu,Reshma A. Rangwala,Martin Reck +17 more
TL;DR: PFS2 and updated OS are presented, finding pembrolizumab (pembro) was superior to chemotherapy (chemo) as first-line (1L) therapy for advanced NSCLC with PD-L1 TPS ≥50% and no sensitizing EGFR mutations or ALK translocations.
Journal ArticleDOI
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.
Aurélien Marabelle,Philippe A. Cassier,Marwan Fakih,Steven Kao,Dorte Nielsen,Antoine Italiano,Tormod Kyrre Guren,Marloes G J van Dongen,Kristen Spencer,Giovanni M. Bariani,Paolo A. Ascierto,Armando Santoro,Sandrine Hiret,Patrick A. Ott,Sarina Anne Piha-Paul,Chih-Chin Liu,Melanie A. Leiby,Kevin Norwood,Jean-Pierre Delord +18 more
TL;DR: A pooled analysis of pembrolizumab (pembro) antitumor activity and treatment options for anal squamous cell carcinoma patients with poor outcomes and few treatment options is reported.
Journal ArticleDOI
KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Shruti Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
Journal ArticleDOI
BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006
Georgina V. Long,Laurent Mortier,Michal Lotem,J.-J. Grob,A. Ribas,Bart Neyns,C. Lebbé,Peter Mohr,A.M. Arance Fernandez,Matteo S. Carlino,Paul Lorigan,Mark R. Middleton,Jacob Schachter,Euan Walpole,C. Blank,Erin Jensen,Melanie A. Leiby,Nuhad K. Ibrahim,C. Robert +18 more